Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BAY-3546828

Generic Name: BAY-3546828

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1

Recruiting

Posted: 2023/09/25

Sponsor:Bayer

ID:NCT06052306

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Bayer Advances Liver Cancer Treatment with First-in-Human Trial of Novel Targeted Alpha Therapy

a month ago

Bayer has initiated a Phase I clinical trial of 225Ac-GPC3 (BAY 3547926), a targeted alpha radiopharmaceutical designed to treat advanced hepatocellular carcinoma by delivering potent radiation directly to cancer cells.

Bayer Advances Pharma Pipeline with Regulatory Filings and Clinical Milestones

4 months ago

Bayer is preparing regulatory submissions for darolutamide for prostate cancer and finerenone for heart failure, building on their market leadership.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy